ODYSSEY OUTCOMES : Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

ODYSSEY OUTCOMES : Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

• Indications for PCSK-9 inhibitors: Adjunct to diet and maximally tolerated statin in patients with heterozygous familial hypercholesterolemia or clinical ASCVD, who need further reduction of LDL-C. (AHA/ACC consensus statement 2017)

• Reduces LDL-C by a mean average of 45-58% from baseline.

• Evolocumab (another PCSK-9 inhibitor) lowered LDL-C by 59% compared to placebo (FOURIER trial)

Infographic

Reference

Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018 Nov 29;379(22):2097-2107.01174. Epub 2018 Nv 7.

>